Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962429 · ClinicalTrials.gov registry record · Phase 2
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00962429: Completed Phase 2 study, sponsored by Oregon Health and Science University.
NCT00962429 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00962429, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
Interventions
- DRUG lipoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT00962429 record still lists
NCT00962429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which lipoic acid is the first listed.
NCT00962429 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00962429 about?
NCT00962429 is a clinical study titled "Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy". The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
What is the current status of trial NCT00962429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2009-02. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00962429?
The interventions under investigation include: lipoic acid (DRUG).
Who is sponsoring clinical trial NCT00962429?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00962429's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia